Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Zhen Long, Jennifer R. Grandis & Daniel E. Johnson. (2022) Emerging tyrosine kinase inhibitors for head and neck cancer. Expert Opinion on Emerging Drugs 27:3, pages 333-344.
Read now
Read now
Ana Marija Sola, Daniel E. Johnson & Jennifer R. Grandis. (2019) Investigational multitargeted kinase inhibitors in development for head and neck neoplasms. Expert Opinion on Investigational Drugs 28:4, pages 351-363.
Read now
Read now
Elena Verzoni, Paolo Grassi, Isabella Testa, Roberto Iacovelli, Pamela Biondani, Enrico Garanzini, Filippo De Braud & Giuseppe Procopio. (2014) Targeted treatments in advanced renal cell carcinoma: focus on axitinib. Pharmacogenomics and Personalized Medicine 7, pages 107-116.
Read now
Read now
Articles from other publishers (18)
Ji Chen, Mengjiao Sun, Chuqin Chen, Meiyun Kang, Bo Qian, Jing Sun, Xiaopeng Ma, Jianfeng Zhou, Lei Huang, Bin Jiang & Yongjun Fang. (2023) Construction of a novel anoikis-related prognostic model and analysis of its correlation with infiltration of immune cells in neuroblastoma. Frontiers in Immunology 14.
Crossref
Crossref
Jakob Michaelis, Markus Grabbert, August Sigle, Mehmet Yilmaz, Daniel Schlager, Christian Gratzke, Arkadiusz Miernik & Dominik Stefan Schoeb. (2022) Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell Carcinoma—Future or the Past?. Cancers 14:15, pages 3777.
Crossref
Crossref
Michael J. Sorich, Fayzah Mutlib, Madelé Dyk, Ashley M. Hopkins, Thomas M. Polasek, Jean‐Claude Marshall, A. David Rodrigues & Andrew Rowland. (2019) Use of Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Axitinib Exposure: A Fresh Approach to Precision Dosing in Oncology. The Journal of Clinical Pharmacology 59:6, pages 872-879.
Crossref
Crossref
Antoine Thiery-Vuillemin, Emeline Orillard, Guillaume Mouillet, Fabien Calcagno, Nadège Devillard, Stéphane Bouchet & Bernard Royer. (2017) Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma. Cancer Chemotherapy and Pharmacology 79:6, pages 1273-1276.
Crossref
Crossref
Ying Chen, Brian I. Rini, Robert J. Motzer, Janice P. Dutcher, Olivier Rixe, George Wilding, Walter M. Stadler, Jamal Tarazi, May Garrett & Yazdi K. Pithavala. (2015) Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. Targeted Oncology 11:2, pages 229-234.
Crossref
Crossref
Hiral Parekh, Julianne Griswold & Brian Rini. (2016) Axitinib for the treatment of metastatic renal cell carcinoma. Future Oncology 12:3, pages 303-311.
Crossref
Crossref
Maikel Herbrink, Bastiaan Nuijen, Jan H.M. Schellens & Jos H. Beijnen. (2015) Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treatment Reviews 41:5, pages 412-422.
Crossref
Crossref
Ying Chen, Akiyuki Suzuki, Michael A. Tortorici, May Garrett, Robert R. LaBadie, Yoshiko Umeyama & Yazdi K. Pithavala. (2015) Axitinib plasma pharmacokinetics and ethnic differences. Investigational New Drugs 33:2, pages 521-532.
Crossref
Crossref
Poupak Fallahi, Valeria Mazzi, Roberto Vita, Silvia Ferrari, Gabriele Materazzi, David Galleri, Salvatore Benvenga, Paolo Miccoli & Alessandro Antonelli. (2015) New Therapies for Dedifferentiated Papillary Thyroid Cancer. International Journal of Molecular Sciences 16:12, pages 6153-6182.
Crossref
Crossref
Hui Zhu & Brian I. Rini. 2015. Renal Cell Carcinoma. Renal Cell Carcinoma
217
236
.
Jing Li, Nan Zhou, Kun Luo, Wei Zhang, Xinru Li, Chuanfang Wu & Jinku Bao. (2014) In Silico Discovery of Potential VEGFR-2 Inhibitors from Natural Derivatives for Anti-Angiogenesis Therapy. International Journal of Molecular Sciences 15:9, pages 15994-16011.
Crossref
Crossref
Helene Sudour-Bonnange, Xavier Leroy, Marie-pierre Chauvet, Marion Classe, P. M. Robin & Pierre Leblond. (2014) Cutaneous metastases during an aggressive course of Xp11.2 translocation renal cell carcinoma in a teenager. Pediatric Blood & Cancer 61:9, pages 1698-1700.
Crossref
Crossref
Yi Gu, Jian Wang, Ke Li, Li Zhang, Hongcan Ren, Lixia Guo, Yang Sai, Weihan Zhang & Weiguo Su. (2014) Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor Fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics. Cancer Chemotherapy and Pharmacology 74:1, pages 95-115.
Crossref
Crossref
Lihong XuJanine StevensMary Beth HiltonSteven SeamanThomas P. ConradsTimothy D. VeenstraDaniel LogsdonHolly MorrisDeborah A. SwingNimit L. PatelJoseph KalenDiana C. HainesEnrique ZudaireBrad St. Croix. (2014) COX-2 Inhibition Potentiates Antiangiogenic Cancer Therapy and Prevents Metastasis in Preclinical Models. Science Translational Medicine 6:242.
Crossref
Crossref
Hiroyuki Takahashi, Hidenori Ojima, Hiroko Shimizu, Junji Furuse, Hiroyuki Furukawa & Tatsuhiro Shibata. (2014) Axitinib (AG-013736), an Oral Specific VEGFR TKI, Shows Potential Therapeutic Utility Against Cholangiocarcinoma. Japanese Journal of Clinical Oncology 44:6, pages 570-578.
Crossref
Crossref
Debra H. Josephs, Danielle S. Fisher, James Spicer & Robert J. Flanagan. (2013) Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. Therapeutic Drug Monitoring 35:5, pages 562-587.
Crossref
Crossref
Ying Chen, Michael A. Tortorici, May Garrett, Brian Hee, Karen J. Klamerus & Yazdi K. Pithavala. (2013) Clinical Pharmacology of Axitinib. Clinical Pharmacokinetics 52:9, pages 713-725.
Crossref
Crossref
Kriti Mittal, Laura S. Wood & Brian I. Rini. (2012) Axitinib in Metastatic Renal Cell Carcinoma. Biologics in Therapy 2:1.
Crossref
Crossref